Deals
Thermo Fisher Extends Binge With $5.2 Billion Patheon Deal
- Patheon makes biological therapies; IPO was in July last year
- Price of $35 a share offers quick post-IPO exit for investors
Thermo Fischer to Buy Patheon in $7.2 Billion Deal
This article is for subscribers only.
Thermo Fisher Scientific Inc. extended its acquisition spree with the $5.2 billion purchase of Dutch drug-ingredients maker Patheon NV.
Thermo Fisher, which has turned into one of the world’s biggest manufacturers of diagnostic and testing equipment through deals, will pay $35 a share in cash for Patheon. That’s 35 percent above Patheon’s closing price Friday, before Bloomberg News reported that the companies were in talks.